These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 2464439)

  • 1. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
    Nemerow GR; Houghten RA; Moore MD; Cooper NR
    Cell; 1989 Feb; 56(3):369-77. PubMed ID: 2464439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA; Chen XS; Holers VM; Hannan JP
    J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
    J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.
    Urquiza M; Lopez R; Patiño H; Rosas JE; Patarroyo ME
    J Biol Chem; 2005 Oct; 280(42):35598-605. PubMed ID: 16087675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
    Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
    J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
    Martin DR; Yuryev A; Kalli KR; Fearon DT; Ahearn JM
    J Exp Med; 1991 Dec; 174(6):1299-311. PubMed ID: 1660522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.
    Tanner J; Whang Y; Sample J; Sears A; Kieff E
    J Virol; 1988 Dec; 62(12):4452-64. PubMed ID: 2460635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.
    Tanner J; Weis J; Fearon D; Whang Y; Kieff E
    Cell; 1987 Jul; 50(2):203-13. PubMed ID: 3036369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.
    Young KA; Herbert AP; Barlow PN; Holers VM; Hannan JP
    J Virol; 2008 Nov; 82(22):11217-27. PubMed ID: 18786993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Epstein-Barr virus envelope glycoprotein gp350 tricks the CR2? A molecular dynamics study.
    Bingöl EN; Taştekil I; Yay C; Keskin N; Ozbek P
    J Mol Graph Model; 2022 Jul; 114():108196. PubMed ID: 35500362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
    EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).
    Moore MD; DiScipio RG; Cooper NR; Nemerow GR
    J Biol Chem; 1989 Dec; 264(34):20576-82. PubMed ID: 2555366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.
    Lowell CA; Klickstein LB; Carter RH; Mitchell JA; Fearon DT; Ahearn JM
    J Exp Med; 1989 Dec; 170(6):1931-46. PubMed ID: 2479703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases.
    D'Addario M; Ahmad A; Morgan A; Menezes J
    J Mol Biol; 2000 May; 298(5):765-78. PubMed ID: 10801347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.
    Martin DR; Marlowe RL; Ahearn JM
    J Virol; 1994 Aug; 68(8):4716-26. PubMed ID: 7913508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
    Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
    J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.